- ►chestpubs.org WH Geerts, GF Pineo, JA Heit, D Bergqvist, … - Chest, 2004 - chestjournal.chestpubs.org This article discusses the prevention of venous thromboembolism (VTE) and is
part of the Seventh American College of Chest Physicians Conference on
Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Grade 1 ... Cited by 3329 - Related articles - BL Direct - All 58 versions
- ►chestpubs.org DE Singer, AS Go - Clinics in geriatric medicine, 2001 - Elsevier Based solely on observational data, long-term anticoagulation has been a favored
therapy to prevent stroke in rheumatic AF. 47 It was unclear whether
anticoagulants would work in nonrheumatic AF or whether they would be ... Cited by 550 - Related articles - BL Direct - All 17 versions
- ►thrombosedialog.de [PDF] S Schulman, K Wahlander, T Lundstrom, SB … - The New England journal of medicine, 2003 - nejm.highwire.org Results Data from 612 patients in the ximelagatran group and 611 in the placebo
group were analyzed. The occurrence of the primary end point, symptomatic
recurrent venous thromboembolism, was confirmed in 12 patients assigned to ... Cited by 347 - Related articles - BL Direct - All 35 versions
CW Francis, SD Berkowitz, PC Comp, JR … - The New England journal of medicine, 2003 - nejm.highwire.org From the Department of Medicine, Univer- sity of Rochester, Rochester, NY (CWF);
the Department of Clinical Development, AstraZeneca, Wilmington, Del. (SDB, GRP,
AWR, JM); the Department of Medicine, University of Oklahoma, Okla- homa ... Cited by 283 - Related articles - BL Direct - All 13 versions
PA Kyrle, S Eichinger - The Lancet, 2005 - Elsevier Deep vein thrombosis and its sequelae pulmonary embolism and post-thrombotic
syndrome are some of the most common disorders. A thrombus either arises
spontaneously or is caused by clinical conditions including surgery, ... Cited by 168 - Related articles - All 14 versions
D Gustafsson, M Elg - Thrombosis Research, 2003 - Elsevier Ximelagatran (Exanta™, AstraZeneca) is a novel, oral direct thrombin inhibitor
(oral DTI) that is rapidly converted to melagatran, its active form, following
absorption. Melagatran has been shown to be a potent, rapidly binding, ... Cited by 158 - Related articles - All 3 versions
- ►vanderbilt.edu [PDF] JR Lieberman, WK Hsu - The Journal of Bone and Joint Surgery, 2005 - JBJS The authors did not receive grants or outside funding in support of their
research or preparation of this manuscript. They did not receive payments or
other benefits or a commitment or agreement to provide such benefits from a ... Cited by 158 - Related articles - BL Direct - All 9 versions
M Bayes, X Rabasseda, JR Prous - Methods and findings in experimental and clinical …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP
Mohana Priya, M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G.
Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
- ►uva.nl [PDF] M Di Nisio, S Middeldorp, HR Buller - New England Journal of Medicine, 2005 - content.nejm.org Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind
directly to thrombin and block its interaction with its substrates. Some DTIs
— such as recombinant hirudins, bivalirudin, and ximelagatran, either ... Cited by 146 - Related articles - BL Direct - All 19 versions
- ►ahajournals.org SZ Goldhaber, CG Elliott - Circulation, 2003 - Am Heart Assoc Pulmonary embolism (PE) presents with a wide clinical spectrum, from
asymptomatic small PE to life-threatening major PE that causes hypotension and
cardiogenic shock (Table). Traditionally, our risk assessment is done by ... Cited by 132 - Related articles - BL Direct - All 4 versions
